[1]王梦霞,贾江花.建立基于磁微粒化学发光免疫分析法检测血清可溶性fms 样酪氨酸激酶-1 的方法及初步性能评价[J].现代检验医学杂志,2024,39(05):193-198.[doi:10.3969/j.issn.1671-7414.2024.05.036]
　WANG Mengxia,JIA Jianghua.Establishment of A Method for Serum Soluble Fms-like Tyrosine Kinase-1 Based on Magnetic Nanoparticle Chemiluminescence Immunoassay and Its Preliminary Performance Evaluation[J].Journal of Modern Laboratory Medicine,2024,39(05):193-198.[doi:10.3969/j.issn.1671-7414.2024.05.036]
点击复制

建立基于磁微粒化学发光免疫分析法检测血清可溶性fms 样酪氨酸激酶-1 的方法及初步性能评价()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年05期
页码:
193-198
栏目:
检验与临床
出版日期:
2024-09-15

文章信息/Info

Title:
Establishment of A Method for Serum Soluble Fms-like Tyrosine Kinase-1 Based on Magnetic Nanoparticle Chemiluminescence Immunoassay and Its Preliminary Performance Evaluation
文章编号:
1671-7414（2024）05-193-06
作者:
王梦霞; 贾江花
（美康生物科技股份有限公司试剂研发中心，浙江宁波 315105）
Author(s):
WANG Mengxia; JIA Jianghua
（R & D Center of IVD Reagents，Medicalsystem Biotechnology Co. Ltd，Zhejiang Ningbo 315105，China）
关键词:
可溶性fms 样酪氨酸激酶-1; 磁微粒化学发光; 子痫前期
分类号:
Q503
DOI:
10.3969/j.issn.1671-7414.2024.05.036
文献标志码:
A
摘要:
目的 基于磁微粒化学发光免疫分析法（chemiluminescence immunoassay，CLIA）建立一种定量检测人血清中可溶性fms 样酪氨酸激酶-1（soluble fms-like tyrosine kinase-1, sFlt-1）含量的方法，并对其性能进行初步评价。方法 采用“三明治”夹心法，血清中的sFlt-1 与生物素化sFlt-1 单克隆抗体和吖啶酯标记的sFlt-1 单克隆抗体反应，形成生物素化抗体- 抗原- 吖啶酯标记抗体的免疫复合物。通过生物素与链霉亲和素的反应，免疫复合物被链霉亲和素包被的磁微粒捕获，标记在免疫复合物上的吖啶酯在碱性H2O2 条件下产生化学发光。利用免疫复合物的光强度计算血清中sFlt-1 的浓度，优化抗体浓度，建立检测sFlt-1 的磁微粒CLIA 方法。对该方法的灵敏度、精密度、线性范围、抗干扰、准确度及方法学比对等性能进行评价。收集2022 年2 ～ 8 月宁波鄞州中医院孕妇血清样本100 份，应用建立的方法进行检测，结果与罗氏电化学发光法检测结果进行比较。结果 最终确定试剂中生物素化抗体的最佳浓度为2 μg/ml，吖啶酯标记抗体的最佳浓度为100 ng/ml。该方法空白限为1.67 pg/ml；批内及批间精密度变异系数（variable coefficient，CV）均＜ 5%；线性范围为8.9 ～ 81 206 pg/ml；血红蛋白浓度不大于500mg/dl，胆红素浓度不大于20mg/dl，乳糜浓度不大于1 450 FTU，生物素浓度不大于50μg/L 时，对检测结果不产生明显干扰；添加回收率为98%；与罗氏电化学发光法比对的相关系数r2 为0.995 3，两组数据之间差异具有统计学意义（P=0.000 3）。结论 建立的方法具有良好的初步性能，进一步开发后可应用于子痫前期的辅助筛查。
Abstract:
Objective To establish a method for soluble fms-like tyrosine kinase-1 (sFlt-1) in human serum based on magnetic nanoparticle chemiluminescence immunoassay and preliminarily evaluate its performance. Methods According to the principle of sandwich plate theory, sFlt-1 in serum reacted with biotinylated anti-sFlt-1 monoclonal antibody and acridinium ester labeled anti-sFlt-1 monoclonal antibody to form an immune complex of biotinylated antibody-antigen-acridinium ester labeled antibody. Through the reaction between biotin and streptavidin, the immune complex was captured by the magnetic nanoparticles coated with streptavidin. The acridinium ester labeled on the immune complex caused chemiluminescence in alkaline H2O2. The chemiluminescence intensity of the immune complex was used to calculate the concentration of sFlt-1 in serum, optimize the concentrations of antibodies, and establish a method for sFlt-1 based on magnetic nanoparticle CLIA. The sensitivity, precision, linear range, interference, accuracy and method comparison of the established method were evaluated. A total of 100 clinical serum specimens were collected from pregnant women in the Ningbo Yinzhou Hospital of Traditional Chinese Medicine from February to August 2022. The established CLIA was used for detection, and the results were compared with the results of Roche electrochemiluminescence assay. Results The optimal concentrations of biotinylated antibody and acridinium ester labeled antibody in the reagent were ultimately determined to be 2μg/ml and 100 ng/ml, respectively. The limit of blank of this method was 1.67 pg/ml, the coefficient of variation (CV) of precision within and between batches was lower than 5%, and the linear range was 8.9 ～ 81 206pg/ml. When the concentrations of serum hemoglobin, bilirubin, fat emulsion and biotin were lower than 500 mg/dl, 20 mg/dl, 1 450 FTU and 50μg/L, respectively, there would be no significant interference with the detected results. The recovery rate of the method was 98%. The correlation coefficient (r2) between the established method and Roche electrochemiluminescence assay was 0.995 3. The difference between the two group was significant (P=0.000 3). Conclusion The established method have good preliminary performance and can be further applied to the auxiliary screening of preeclampsia.

参考文献/References:

[1] MAYRINK J, COSTA M L, CECATTI J G. Preeclampsia in 2018: revisiting concepts, physiopathology, and prediction[ J]. Scientific World Journal, 2018, 2018: 6268276.
[2] CHAIWORAPONGSA T, ROMERO R, GOTSCH F, et al. Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood[J]. American Journal of Obstetrics and Gynecology, 2023, 228(5): 569.e1-569.e4.
[3] DOCHEVA N, ARENAS G, NIEMAN K M, et al. Angiogenic biomarkers for risk stratification in women with preeclampsia[J]. Clinical Chemistry, 2022, 68(6): 771-781.
[4] COSTA R A, HOSHIDA M S, ALVES E A, et al. Preeclampsia and superimposed preeclampsia: the same disease? the role of angiogenic biomarkers[J]. Hypertension in Pregnancy, 2016, 35(2): 139-149.
[5] BEN ALI GANNOUN M, BOURRELLY S , RAGUEMA N, et al. Placental growth factor and vascular endothelial growth factor serum levels in Tunisian Arab women with suspected preeclampsia[J]. Cytokine, 2016, 79: 1-6.
[6] JEON H R, JEONG D H, LEE J Y, et al. sFlt-1/ PlGF ratio as a predictive and prognostic marker for preeclampsia[J]. Journal of Obstetrics and Gynaecology Research, 2021, 47(7): 2318-2323.
[7] CLARK D E, SMITH S K, HE Y, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation[J]. Biology of Reproduction, 1998, 59(6): 1540-1548.
[8] HORNIG C, BARLEON B, AHMAD S, et al. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids[J]. Laboratory Investigation, 2000, 80(4): 443-454.
[9] PALMER K R, TONG S, KAITU'U-LINO T J. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis[J]. Molecular Human Reproduction, 2017, 23(2): 69-78.
[10] Clinical and Laboratory Standards Institute. EP17. Evaluation of detection capability for clinical laboratory measurement procedures[S]. 2nd Ed. Wayne: PA, CLSI EP17-A2, 2012.
[11] Clinical and Laboratory Standards Institute. EP05-A3. Evaluation of precision of quantitative measurement procedures; approved guideline[S]. 3rd Ed. Wayne: PA, CLSI EP05-A3, 2014.
[12] National Committee for Clinical Laboratory Standards. EP6-A. Evaluation of the linearity of quantitative measurement procedures: a statistical approach,approved guideline[S]. Wayne: PA, NCCLS EP6-A. 2003.
[13] Clinical and Laboratory Standards Institute. EP07-A2. Interference testing in clinical chemistry; approved guideline[S]. 2nd Ed. Wayne: PA, CLSI EP07-A2, 2005.
[13] Clinical and Laboratory Standards Institute. EP07. Interference testing in clinical chemistry[S]. 3rd Ed. Wayne: PA, CLSI EP07, 2018.
[14] American College of Obstetricians and Gynecologists. ACOG practice bulletin no.202 gestational hypertension and preeclampsia[J]. Obstetrics and Gynecology, 2019,133(1):1.
[15] TAKAKURA S, TANAKA H, TAMAISHI Y, et al. The role of periodic measurement of sFlt-1 and PlGF in predicting the remaining pregnancy duration in hypertensive disorders of pregnancy[J]. Pregnancy Hypertension, 2023, 34: 104-109.
[16] GIARDINI V, GRILLI L, TERZAGHI A, et al. sFlt- 1 levels as a predicting tool in placental dysfunction complications in multiple pregnancies[J]. Biomedicines, 2023, 11(11): 2917.
[17] 徐晓锋, 郭历琛, 徐玲, 等. 孕妇血清PLGF, sFlt-1, Ca2+, 25-(OH)-D 水平检测及其他危险因素分析对预测子痫前期的临床意义[J]. 现代检验医学杂志,2019, 34(5): 35-39. XU Xiaofeng, GUO Lichen, XU Ling, et al. Clinical significance of serum PLGF, sFlt-1, Ca2+, 25-(OH)-D levels and other risk factors in pregnant women in predicting preeclampsia[J]. Journal of Modern Laboratory Medicine, 2019, 34(5): 35-39.
[18] 吴鸿峰, 邓昊, 翁孔燕, 等. 可溶性fms 样酪氨酸激酶1 时间分辨荧光免疫分析法的建立[J]. 现代免疫学, 2022, 42(5): 375-380. WU Hongfeng, DENG Hao, WENG Kongyan, et al. Establishment of time-resolved fluoroimmunoassay for soluble fms-like tyrosine kinase 1[J]. Current Immunology, 2022, 42(5): 375-380.

相似文献/References:

[1]胡　艺,何熙国,周琮凯.血清sFlt-1，PTX-3，D-二聚体水平对ERCP术后胰腺炎严重程度的相关性及预测价值研究[J].现代检验医学杂志,2021,36(04):142.[doi:10.3969/j.issn.1671-7414.2021.04.031]
　HU Yi,HE Xi-guo,ZHOU Cong-kai.Study on the Correlation and Predictive Value of Serum sFlt-1, PTX-3,D-dimer Levels and the Severity of Post-ERCP Pancreatitis[J].Journal of Modern Laboratory Medicine,2021,36(05):142.[doi:10.3969/j.issn.1671-7414.2021.04.031]
[2]谭玉华,于 婷,余海枷,等.基于生物素 亲和素时间分辨荧光免疫法检测血清可溶性fms样酪氨酸激酶-1的方法建立及性能评价[J].现代检验医学杂志,2025,40(02):186.[doi:10.3969/j.issn.1671-7414.2025.02.035]
　TAN Yuhua,YU Ting,YU Haijia,et al.Establishment and Performance Evaluation of Method for Detecting Serum Soluble fms Like Tyrosine Kinase-1 Based on Biotin-avidin System Timeresolved Fluorescence Immunoassay[J].Journal of Modern Laboratory Medicine,2025,40(05):186.[doi:10.3969/j.issn.1671-7414.2025.02.035]

备注/Memo

备注/Memo:
作者简介： 王梦霞（1991-），女，本科，生物工程中级工程师，三级健康管理师，研究方向：免疫学诊断试剂的研制，E-mail：601895076@qq.com。
更新日期/Last Update: 2024-09-15